Compare GSK plc (GSK) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Prologis Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Prologis Inc trades at $129.49 (market cap $122.87B). The key difference: Prologis Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Prologis Inc for 102 Days on average.
| GSK | PLD | |
|---|---|---|
Market Cap | $91.88B | $122.87B |
Volume | 7,730,529 | 4,222,957 |
Sector | Health | Real Estate |
52-Week High | $61.18 | $149.96 |
52-Week Low | $43.24 | $111.23 |
Typical Hold Time | 93 Days | 102 Days |
Enterprise Value | $111.88B | $157.61B |
Dividend Yield | 3.9% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
PLD trades at $129.29, up 1.56% today, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, with Q2 2026 EPS of $1.13 versus $0.747 expected. The company shows robust revenue growth, reaching $8.79B in 2025, and maintains high profitability with a net income margin of 45.79%. News highlights leasing surges and data center growth, supporting a positive long-term outlook despite near-term price volatility.
The outlook for PLD is positive, driven by strong industrial REIT demand, earnings beats, and a consensus price target of $155.15 offering ~20% upside. Risks include rising debt-to-asset ratios (37.2% in 2025) and macroeconomic sensitivity. Analyst sentiment is bullish with 59.52% buy ratings, but investors should monitor debt levels and interest rate impacts on valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
